Dr. William A. Pearce, M.D.
Ophthalmology (Ophthalmology Physician)
- Medicare participating
At a glance
- Medical school
- University of Texas Medical Branch at Galveston (2012)
- Years since graduation
- 14
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 685
Licensed in Texas since 2021, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Medical school: University of Texas Medical Branch at Galveston
- 2012Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
TX license T1514 (first issued 2021; active) · TX license BP10042832
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Christus Southeast Texas- St Elizabeth Beaumont, TX
Medical groups
- Retina Consultants of Houston PLLC (25 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 685
- Services billed
- 12,408
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Imaging of retina | 1,181 | 455 |
| Injection, aflibercept, 1 mg | 900 | 96 |
| Established patient complete exam of visual system | 603 | 318 |
| Injection of drug into eye | 570 | 129 |
| Injection, ranibizumab, 0.1 mg | 295 | 14 |
| New patient complete exam of visual system | 159 | 159 |
| New patient office or other outpatient visit, 45-59 minutes | 91 | 91 |
| Photography of the retina | 86 | 79 |
| Extended exam of the back part of the eye with retinal drawing | 41 | 34 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 40 | 40 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in Beaumont, TX | 109 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Beaumont, TX | 49 |
| Ketorolac Tromethamine Other prescribers in Beaumont, TX | 43 |
| Bromfenac Sodium | 39 |
| Latanoprost Other prescribers in Beaumont, TX | 31 |
| Brimonidine Tartrate Other prescribers in Beaumont, TX | 23 |
| Dorzolamide Hcl Other prescribers in Beaumont, TX | 19 |
| Difluprednate | 17 |
| Prolensa (bromfenac sodium) | 17 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Beaumont, TX | 16 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 20 payments worth $679 in total to this clinician.
| Apellis Pharmaceuticals, Inc. | $242 |
|---|---|
| AbbVie Inc. | $221 |
| Regeneron Healthcare Solutions, Inc. | $120 |
| Astellas Pharma US Inc | $65.30 |
| Genentech USA, Inc. | $30.47 |
| Food and Beverage | $679 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 4 companies. The companies reported $669,960 in research payments for these studies, mostly to the institutions running them.
- A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT06491914 - Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration
Ocular Therapeutix, Inc. - A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular dege…
Boehringer Ingelheim Pharmaceuticals, Inc. - JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862
Boehringer Ingelheim Pharmaceuticals, Inc. - A Phase I, open-label multi-center dose-escalation trial of BI 765049 administered by parenteral route in patients with advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), gastric carcinoma, or PDAC …
Boehringer Ingelheim Pharmaceuticals, Inc. - A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular dege…
Boehringer Ingelheim International GmbH - JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.